Ocular drug delivery systems: An overview. - Wikidata - awgldk - TriplyDB

Ocular drug delivery systems: An overview.

Ocular drug delivery systems: An overview.

http://www.wikidata.org/entity/Q38318837

about

In Vitro Cell Models for Ophthalmic Drug Development Applications Recent advances in protein and Peptide drug delivery: a special emphasis on polymeric nanoparticles Dexamethasone diffusion across contact lenses is inhibited by Staphylococcus epidermidis biofilms in vitro.A Drug Delivery System for Administration of Anti-TNF-α Antibody.Investigation of Diffusion Characteristics through Microfluidic Channels for Passive Drug Delivery Applications Recent developments in protein and peptide parenteral delivery approaches.Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions.Contact lenses as drug reservoirs & delivery systems: the successes & challenges.The role of nanotechnology in control of human diseases: perspectives in ocular surface diseases.Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.Recent developments in ocular drug delivery.Nanotechnology: from In Vivo Imaging System to Controlled Drug Delivery.Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: Effect of molecular weight and density of poly (ethylene) glycol.Nanocarrier fabrication and macromolecule drug delivery: challenges and opportunities Anti-Toxoplasma activity and impact evaluation of lyophilization, hot molding process, and gamma-irradiation techniques on CLH-PLGA intravitreal implants.Ultrasound-mediated ocular delivery of therapeutic agents: a review.Recent perspectives on the delivery of biologics to back of the eye.Triamcinolone acetonide nanoparticles incorporated in thermoreversible gels for age-related macular degeneration.A comprehensive insight on ocular pharmacokinetics.Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.Enhancement of lomefloxacin Hcl ocular efficacy via niosomal encapsulation: in vitro characterization and in vivo evaluation.Comparison of Different Nanosuspensions as Potential Ophthalmic Delivery Systems for Ketotifen Fumarate.Therapeutic Potential of Shark Anti-ICOSL VNAR Domains is Exemplified in a Murine Model of Autoimmune Non-Infectious Uveitis.Distribution of Triamcinolone Acetonide after Intravitreal Injection into Silicone Oil-Filled Eye Dendrimers for Ocular Drug Delivery.Pediatric ocular nanomedicines: Challenges and opportunities.Alternative Drug Delivery for Patients Undergoing Cataract Surgery as Demonstrated in a Canine Model.Pharmacodynamic profile of mydriatic agents delivered by ocular piezo-ejection microdosing compared with conventional eyedropper.Ultrahigh field MR imaging of a subconjunctival anti-glaucoma drug delivery system in a rabbit model.Ocular Nerve Growth Factor (NGF) and NGF Eye Drop Application as Paradigms to Investigate NGF Neuroprotective and Reparative Actions.Poly(ε-caprolactone) nanocapsule carriers with sustained drug release: single dose for long-term glaucoma treatment.How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches.Transcleral approach for closing retinal tears using DuraSeal™ hydrogel sealant.Preparation and evaluation of PCL-PEG-PCL micelles as potential nanocarriers for ocular delivery of dexamethasone.Ophthalmic Drug Delivery Systems for Antibiotherapy-A Review.A novel ion-activated in situ gelling ophthalmic delivery system based on κ-carrageenan for acyclovir.Recent advances in topical nano drug-delivery systems for the anterior ocular segment.High-precision piezo-ejection ocular microdosing: Phase II study on local and systemic effects of topical phenylephrine.Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in the Treatment of Experimental Uveitis Rabbit.Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues.

P2860

Q26751148-8867F67B-DD56-4FE3-BD6B-75872754FA08 Q27028129-09C899F7-C69F-4503-90F9-76F88F7E52E8 Q34156665-AEB1D635-3C90-4016-8D56-80EBAADEA770 Q36683809-0205A62C-4763-4F4E-8845-492F3CB3C179 Q36985582-0F3395A8-D7D5-40FD-A627-25429C9BC46B Q38193174-26B68965-2DF2-43B9-877C-941DF5C09F51 Q38227621-2777A51F-EFEE-4560-9B19-A861B7B2F402 Q38270688-8A824885-C74C-480F-8C88-189B850B263C Q38550131-ACAC4A40-E1AB-4B4F-AB94-3E820976CBEF Q38584194-76BD3CDF-0B4A-4E2A-90D8-3FC7B2EFC49E Q38603354-BB477C55-83F5-4E93-9CD1-151775C0F5B4 Q38640456-F7CAC349-9EA9-4D1E-ADB9-A7FC0756B389 Q38716544-1260A967-0D68-4395-9AAA-44EC70BD199C Q38787324-7DBAA904-4366-4D7E-9649-CBF3BADA1AE8 Q38811119-6454BE01-79DA-4F73-9899-30B6C1A2FB25 Q38867140-4C4365C9-698E-4389-989A-A8DBFBF10315 Q38940171-7411649D-5CD2-4AF7-8933-4DE16870502B Q38953075-0E9ECC06-9A86-40E4-BB4C-FFB09D12DA36 Q38995367-00B94D8E-AAEA-4A22-9C3D-0F5B0BA88937 Q39087808-3092AA51-6A21-4A07-BC77-F175D81813B0 Q40653236-3748D66E-BC17-4A4B-9E6A-241FF6319994 Q41513479-210CD70D-0CF1-426C-BCE4-10DD4BDF8162 Q41989317-F2137121-D35F-478A-99D9-24C5A82243F0 Q42398866-0FFB2084-4E38-4341-9D92-02356E0DBE51 Q45073183-2B93C93F-4FBC-4C07-9881-58B781FDBD8B Q45073189-49FD9D4A-CC37-470D-9020-FF660B7C49C9 Q46545095-028B20B7-0B75-4A7A-958D-368725510B06 Q46968848-DF5000EA-3534-4C64-947F-8ABFDDE5FF62 Q47142392-6E120A20-4F32-4B42-84FF-2D5AB41E0B2F Q47339159-CD816A73-EEF4-424A-A10B-6FBFD09540EE Q47826142-86015DA7-E3DC-439F-87CA-C164FB63B299 Q48902538-4EA733EC-08E4-4285-83E9-8B2FEF5690A6 Q49584415-90BEE768-6EDE-42C3-8DB1-54E2E399CBB6 Q49874284-2B3F6D3E-3D7F-4E02-8248-D9B5EA83D2D4 Q49996892-7BC50633-3E51-42C7-A143-A55B02B13FCD Q50047575-67FB11CB-7E44-4DAE-BDB5-C6ACD033EBDC Q50082031-6B6F09A4-4F07-4788-9894-B2B6C3A19BDC Q50094851-2B0DD2F9-E41B-4D75-BC9E-827E370B7458 Q50097437-39B3B3D8-6EB0-412F-86A6-B11E4A822A45 Q50278439-63FC53C1-597F-4EC1-B487-86C0D39EE92F

P2860

Ocular drug delivery systems: An overview.

http://www.wikidata.org/entity/Q38318837

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Ocular drug delivery systems: An overview.

@en

type

label

Ocular drug delivery systems: An overview.

@en

prefLabel

Ocular drug delivery systems: An overview.

@en

P1433

Q38318837-685CE67E-537D-416A-BFC0-3065C8C8B2CC

P1476

Q38318837-C0F9558C-AF15-4BD4-92CD-FEBC2881F2B3

P2093

Q38318837-38D1526F-EFE7-4908-9098-7C037DAF32F8

Q38318837-82626AEB-70B7-452E-94CF-FF0C857D5F50

Q38318837-BD912EB6-089D-46B9-BBB0-F7FC5E604F1D

Q38318837-DB07419B-A8CC-47A3-B7DE-8DB3C40EB623

P2860

Q38318837-01D9F3BF-09E8-4AB0-B8A5-8BF5D46089BE

Q38318837-02073C0F-400A-4114-AF22-B75B57E2E85A

Q38318837-0788CC98-9B1D-43F7-A24C-A994289DE437

Q38318837-079FC8E4-15F2-4180-9B96-C6F74A4DEF38

Q38318837-08A10613-1BB1-4BB5-8986-9BA12908F61C

Q38318837-0F36D47A-28CE-4887-B405-6C7FD51BBD82

Q38318837-13FA07C3-5FCF-4C0B-82D5-D9FD3BC2FD32

Q38318837-1AE96744-9AE0-42EF-B40F-383C773C02E7

Q38318837-1B451E11-80C3-47CD-B4AF-C82F40D56324

Q38318837-1CB9F1CA-0912-4BB3-B771-1EBB55851011

P304

Q38318837-17506CE7-33D0-4511-99AE-1DFC54D5FF1C

P31

Q38318837-116BD5E2-317D-4768-9D08-0CAA6173FC1E

P356

Q38318837-6010EDA8-500E-4E87-9CAB-D047A6EA2CE7

P433

Q38318837-BFD8CF9D-0C43-4A23-8FB0-6D6902DAA07D

P478

Q38318837-32008608-F22F-4F3B-A40B-872BCAE1DC65

P577

Q38318837-522ACF82-6D0B-4B94-99ED-6D22BC26EC00

P5875

Q38318837-1EA9E4E5-CC0E-4089-8358-E9935F08008F

P698

Q38318837-824D5512-7646-4F2E-B536-CE9F221D699B

P921

Q38318837-8C2D8A89-C902-414C-BE30-09420BEFB921

P932

Q38318837-64B361C9-ED2F-445C-A79F-3E25AFB4A18F

P356

P1433

World journal of pharmacology

P1476

Ocular drug delivery systems: An overview.

@en

P2093

Ashaben Patel

http://www.w3.org/2001/XMLSchema#string

Ashim K Mitra

http://www.w3.org/2001/XMLSchema#string

Kishore Cholkar

http://www.w3.org/2001/XMLSchema#string

Vibhuti Agrahari

http://www.w3.org/2001/XMLSchema#string

P2860

Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye

Ocular drug delivery.

Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride.

Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina.

Enhancement of ocular drug penetration.

Intrascleral drug delivery to the eye using hollow microneedles.

Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety.

[A new therapy concept for the treatment of dry eye--the usefulness of phospholipid liposomes]

Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery.

Suprachoroidal drug delivery to the back of the eye using hollow microneedles

P304

47-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5497/WJP.V2.I2.47

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270964184

http://www.w3.org/2001/XMLSchema#string

P698

25590022

http://www.w3.org/2001/XMLSchema#string

P921

P932

4289909

http://www.w3.org/2001/XMLSchema#string